Catalyst
Slingshot members are tracking this event:
CTI Biopharma (CTIC) Plans to Initiate PAC203 Trial in Q2 2017 Evaluating Pacritinib in Patients with Primary Myelofibrosis Who Have Failed Prior Ruxolitinib Therapy
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| CTIC |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 24, 2017
Occurred Source:
https://clinicaltrials.gov/ct2/show/NCT03165734
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Pac203, Pacritinib, Primary Myelofibrosis, Ruxolitinib
